Boston Scientific Cuts Annual Profit Forecast on Weaker Watchman Demand

Boston Scientific has revised its 2024 profit forecast downward due to softer-than-expected demand for its heart device, Watchman. The company stated that the slowdown in sales of this product has negatively impacted its overall financial outlook. According to the new estimates, Boston Scientific's adjusted earnings per share (EPS) will fall below previous expectations. Despite growth in other product lines, the weakness in this heart device is pressuring overall profitability, the company said. Analysts believe the decline in Watchman demand may be temporary but could narrow the company's margins in the short term. Boston Scientific plans to focus on cost control and new product launches to offset this situation. This is not investment advice.

📊 BSX — Piyasa Yorumu

▼ down · 70%

The news headline indicates that Boston Scientific has lowered its annual profit forecast due to weakening demand for its Watchman product. This signals a slowdown in the company's key growth driver and could put pressure on the stock. Technically, while the RSI is neutral at 59, the MACD line has just crossed below the signal line, which may be interpreted as a short-term weakening signal. Although the last closing price is above the 20- and 50-day moving averages, the negative news flow and the MACD crossover support a bearish trend in the short term.

RSI 14

59.3

MACD

0.66

24h Δ

6.03%

Canlı Grafikler